Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885455 | 0.84 | RAB9A (0.62) | KMT2ATP53CYP3A4HTTKDM4E | |
| SCHEMBL4767293 | 0.83 | HSD17B10 (0.54) | KMT2ATP53CYP3A4KDM4EALDH1A1 | |
| SCHEMBL7606595 | 0.82 | KMT2A (0.70) | KMT2AHTTALDH1A1RAB9ALMNA | |
| SCHEMBL217079 | 0.82 | CYP3A4 (0.56) | KMT2ATP53CYP3A4KDM4EALDH1A1 | |
| SCHEMBL10753958 | 0.81 | CYP3A4 (0.59) | KMT2ATP53CYP3A4KDM4EALDH1A1 | |
| SCHEMBL24863820 | 0.81 | KMT2A (0.54) | KMT2AHTTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL16180109 | 0.81 | HSD17B10 (0.70) | KMT2AHTTKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8428158 | 0.81 | GAA (0.58) | KMT2ATP53HTTKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL5177536 | 0.80 | KMT2A (0.61) | KMT2ATP53HTTKDM4EALDH1A1 | |
| SCHEMBL778673 | 0.80 | MEN1 (0.52) | KMT2ATP53KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271631-B1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2834237-B1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| US-9969731-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2018-05-15 | — | — | US | disclosed |
| US-20180064646-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2017-04-13 | — | — | US | disclosed |
| US-9555035-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20160331753-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2016-11-17 | — | — | US | disclosed |
| US-9428499-B2 | Heterocyclyl compounds as MEK inhibitors | LUPIN LIMITED (IN) | 2016-08-30 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | LUPIN LIMITED (IN) | 2015-05-14 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009031011-A2 | XINAFOATE SALT OF N4-(2, 2-DIFLUORO-4H-BENZ0 [1,4] 0XAZIN-3-ONE) -6-YL] -5-FLUORO-N2- [3- (METHYLAMINOCAR BONYLMETHYLENEOXY) PHENYL] 2, 4-PYRIMIDINEDIAMINE | PFIZER LIMITED (GB) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008024634-A1 | PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| EP-1471915-A4 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | EP | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225321-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | KMT2A 2984/4885TP53 1171/4885CYP3A4 1599/4885 |
| US-20160331753-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | KMT2A 1291/4885TP53 399/4885CYP3A4 570/4885 |
| US-20150133424-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | KMT2A 1291/4885TP53 399/4885CYP3A4 570/4885 |
| US-20180064646-A1 | METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO[1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3-(METHYLAMINOCARBONYLMETHYLENEOXY)PHENYL]2,4-PYRIMIDINEDIAMINE | YTHDF1, YTHDF2, YTHDF3 | KMT2A 1105/4885TP53 4570/4885CYP3A4 320/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | KMT2A 1671/4885TP53 1024/4885CYP3A4 829/4885 |
| US-20170101408-A1 | HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS | NRAS, BRAF, KRAS | KMT2A 1291/4885TP53 399/4885CYP3A4 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.